<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E48B12F2-D13E-4A21-9010-BCA635CCC6C2"><gtr:id>E48B12F2-D13E-4A21-9010-BCA635CCC6C2</gtr:id><gtr:firstName>Garry</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A509C636-C961-4A35-A8C3-810A1FBCA334"><gtr:id>A509C636-C961-4A35-A8C3-810A1FBCA334</gtr:id><gtr:firstName>Bernadette</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Dutia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A4B8A8F7-6587-4F11-A2C0-5E7D1D7DC7C7"><gtr:id>A4B8A8F7-6587-4F11-A2C0-5E7D1D7DC7C7</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Nash</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/32248348-4DCD-4468-B6B4-43F8813A144A"><gtr:id>32248348-4DCD-4468-B6B4-43F8813A144A</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>CONNARIS</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0902201"><gtr:id>CFD17B09-289C-481A-961F-0E18772A33F2</gtr:id><gtr:title>Multivalent therapeutic proteins for influenza</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902201</gtr:grantReference><gtr:abstractText>Influenza continues to be a global threat with the potential for great loss of life and disruption to society and commerce. Governments have been stockpiling huge amounts of the two antivirals Relenza and Tamiflu, both of which are $1 billion drugs. The influenza virus has the capacity to mutate or to generate completely new viruses, in terms of their assault on our immune system, through mixing of its genetic segments. Sadly, circulating H1N1 viruses have already developed resistance to Tamiflu. Vaccines are generally effective, but take a long time to generate and recent vaccines for pandemic swine H1N1 have had reported side effects. We are taking the novel approach of blocking the attachment sites in the respiratory tract that the influenza virus requires for infection. We have developed proteins that bind tightly to these receptors (sugar molecules called sialic acids), and they halt a lethal infection of influenza in a mouse model. Our approach has the potential to be a drug against any current and future strain of influenza and potentially parainfluenza that uses the same receptors, and could be a first line of defence in a pandemic or a prophylactic for high-risk patients.</gtr:abstractText><gtr:technicalSummary>Influenza continues to be a global health threat, with a constant requirement for new therapies. We have approached this need by engineering a panel of multivalent proteins constructed using carbohydrate-binding modules derived from the Vibrio cholerae and Streptococcus pneumoniae sialidases. These multivalent proteins have up to nanomolar binding affinity for sialic acid - the binding receptor for (para)influenza viruses - found on mammalian cell surfaces of the respiratory tract. Preliminary in vivo studies in mice have shown that they are tolerant to the proteins, and that they are effective in preventing disease when applied one day before or on the day of viral infection. We propose that these multivalent proteins be considered as biologics for use as a prophylactic against pandemic influenza. We will carry out further in vivo studies (at Edinburgh and at St Jude, Memphis) to examine dosage and delivery of the proteins and will study any immune response elicited by them, and devise de-immunisation strategies if neccessary. The aim is to identity a lead biologic for further development. We believe that this approach of targeting the host rather than the virus should minimize problems of drug resistance.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>636290</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention is based on the finding that in addition to interfering with or blocking, preventing and/or inhibiting the interaction between a pathogen and, for example, a sialic acid containing cell surface receptor, certain sialic acid binding molecules have immunomodulatory properties. The invention provides methods and uses which exploit sialic acid binding molecules in the treatment and/or prevention of disease by modulation and/or priming of the host immune response.</gtr:description><gtr:id>C780B5B6-B7AB-4B9D-9095-472318679825</gtr:id><gtr:impact>Creation of University spinout Pneumagen.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2015110831</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Immunomodulatory Compounds</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.</gtr:description><gtr:id>9DCE0DF4-55A9-4409-98B5-BB5FB5EDB04D</gtr:id><gtr:impact>Creation of University spinout Pneumagen.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2010029312</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Carbohydrate binding molecules</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/545B1EFB-E157-4B5C-837A-F665DB95478F"><gtr:id>545B1EFB-E157-4B5C-837A-F665DB95478F</gtr:id><gtr:title>Structural characterization of the carbohydrate-binding module of NanA sialidase, a pneumococcal virulence factor.</gtr:title><gtr:parentPublicationTitle>BMC structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-6807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5EF33A67-2990-4EB9-9FAD-F2A0161289F9"><gtr:id>5EF33A67-2990-4EB9-9FAD-F2A0161289F9</gtr:id><gtr:title>Prevention of influenza by targeting host receptors using engineered proteins.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e39c0271d699747762754ec2b1a574d"><gtr:id>0e39c0271d699747762754ec2b1a574d</gtr:id><gtr:otherNames>Connaris H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6795727F-CE97-4FAE-BAA8-DA4DF2BEFFAB"><gtr:id>6795727F-CE97-4FAE-BAA8-DA4DF2BEFFAB</gtr:id><gtr:title>Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fb25fce01593a2492981eb085594c7d6"><gtr:id>fb25fce01593a2492981eb085594c7d6</gtr:id><gtr:otherNames>Govorkova EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902201</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>